STOCK TITAN

Arrowhead Research Corporation - ARWR STOCK NEWS

Welcome to our dedicated page for Arrowhead Research Corporation news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Research Corporation stock.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is a leading clinical-stage biotechnology company dedicated to developing innovative medicines that address intractable diseases through gene silencing. The company utilizes an extensive array of RNA chemistries and efficient delivery systems to harness the power of RNA interference (RNAi) mechanisms. This approach allows for the rapid, deep, and durable knockdown of target genes, thereby reducing the production of specific proteins that cause diseases.

Arrowhead's groundbreaking therapies are at the forefront of genetic-based treatments, presenting potential life-changing solutions for patients. Notable among their technologies is the Targeted RNAi Molecule (TRiMTM) platform. This platform employs ligand-mediated delivery for tissue-specific targeting while maintaining structural simplicity. The TRiMTM platform is built upon over a decade of research in actively targeted drug delivery, offering advantages such as simplified manufacturing processes and enhanced specificity.

The company's diverse portfolio includes promising treatments for conditions such as Hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular diseases. Arrowhead is continuously engaged in advancing its clinical programs and forging strategic partnerships to bring its novel therapies to market.

With headquarters in Pasadena, California, Arrowhead Pharmaceuticals remains committed to transforming the landscape of genetic medicine and improving patient outcomes worldwide. Their dedication to scientific innovation and patient care positions them as a pivotal player in the biotechnology sector.

Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has approved inducement grants for 34 new employees on July 1, 2022. The grants comprise a total of 138,000 restricted stock units, with 70,000 units awarded to the new chief commercial officer, Tracie Oliver. These grants are outside the company's stockholder-approved equity incentive plans and will vest over four years. Arrowhead focuses on developing RNA interference-based therapies to treat severe diseases by silencing problematic genes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
none
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated dosing in two Phase 1/2a clinical trials for ARO-MUC5AC and ARO-RAGE, innovative RNA interference therapeutics targeting mucin production and inflammatory responses in lung diseases. ARO-MUC5AC-1001 and ARO-RAGE-1001 trials aim to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and asthma patients. CEO Chris Anzalone highlighted this as a pivotal milestone in the company's mission to tackle difficult-to-drug targets in respiratory conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.9%
Tags
-
Rhea-AI Summary

Takeda (TAK) and Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced promising results from the Phase 2 AROAAT-2002 study of fazirsiran for liver disease due to alpha-1 antitrypsin deficiency (AATD). Key findings include a 58% fibrosis regression in treated patients, an 83% median reduction in Z-AAT accumulation in the liver, and a 69% reduction in histologic globule burden. Fazirsiran aims to tackle AATD's liver manifestations, with plans for a Phase 3 study on the horizon. The collaboration has received Breakthrough Therapy and Orphan Drug designations from the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is set to participate in several key healthcare conferences in June 2022. Events include the Jefferies Healthcare Conference from June 8-10 and the Goldman Sachs 43rd Annual Global Healthcare Conference from June 13-16, both featuring presentations by Vincent Anzalone, Vice President Finance and Investor Relations.

Additionally, they will present at The International Liver Congress™ 2022, discussing significant studies related to chronic hepatitis B. Further details can be accessed through their Events and Presentations webpage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
conferences
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is hosting a pulmonary R&D Day in New York City to unveil its pipeline of RNA interference therapeutics targeting pulmonary diseases. Key presentations include ARO-MUC5AC, ARO-RAGE, and ARO-MMP7, aimed at treating muco-obstructive and inflammatory conditions. ARO-RAGE shows over 90% mRNA reduction in preclinical studies, while ARO-MUC5AC promises significant silencing of pathogenic expression. ARO-MMP7 targets idiopathic pulmonary fibrosis. The event will enhance confidence in upcoming clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported strong financial results for Q2 FY2022, demonstrating a revenue increase to $151.8 million, up from $32.8 million in Q2 FY2021. The company achieved a net income of $44.4 million, or $0.41 per diluted share, compared to a loss of $26.8 million in the previous year. Key developments include the initiation of several clinical studies for its investigational RNA interference therapeutics, which target various conditions, alongside the formation of a joint venture in Greater China and the groundbreaking of a new manufacturing facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.57%
Tags
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has commenced construction on a new drug manufacturing facility in Verona, WI, expected to span about 160,000 square feet, alongside a 125,000 square foot laboratory and office space. The company has been awarded $16 million in tax increment financing from Verona and $2.5 million in refundable income tax credits from the Wisconsin Economic Development Corporation. Completion of the lab is anticipated by 2023, while the manufacturing facility is expected to finish in 2024, aiming to support the development of innovative RNAi-based therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.38%
Tags
none
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) appointed Victoria Vakiener as an independent director, effective May 2, 2022. Vakiener brings extensive experience, including leadership roles at Epizyme and Johnson & Johnson, aimed at guiding Arrowhead's growth in RNAi technology commercialization. Chairman Douglass Given praised her ability to help the company transition into a commercial stage. This strategic addition underscores Arrowhead's commitment to enhancing its leadership as it focuses on advancing its innovative gene-silencing therapies to tackle intractable diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
management
-
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in several upcoming conferences in May 2022. Events include TIDES USA 2022 from May 9-12, where Michael Lawler will discuss scale-up manufacturing. At the American Thoracic Society Conference from May 13-18, David Kasahara will present on RNAi delivery platforms targeting lung inflammation. Arrowhead will also participate in the BofA Securities Healthcare Conference and the RBC Capital Markets Healthcare Conference on May 12 and 17, respectively, both featuring Christopher Anzalone. Further details are available on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
conferences
Rhea-AI Summary

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a pulmonary research & R&D day on May 26, 2022, from 10:00 a.m. to 1:00 p.m. ET in New York City. The event will discuss its pipeline of pulmonary targeted RNA interference (RNAi) therapies, featuring key opinion leaders, Dr. Mario Castro and Dr. Matthias Salathe. Presentations will cover ARO-MUC5AC and ARO-RAGE, investigational RNAi candidates targeting muco-obstructive and inflammatory pulmonary diseases. Attendance is limited to institutional investors and analysts; RSVP is required.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
conferences

FAQ

What is the current stock price of Arrowhead Research Corporation (ARWR)?

The current stock price of Arrowhead Research Corporation (ARWR) is $19.45 as of December 20, 2024.

What is the market cap of Arrowhead Research Corporation (ARWR)?

The market cap of Arrowhead Research Corporation (ARWR) is approximately 2.5B.

What is the primary focus of Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals focuses on developing gene-silencing therapies to treat intractable diseases by targeting the genes that cause them.

What is RNA interference (RNAi)?

RNA interference (RNAi) is a natural mechanism in living cells that inhibits the expression of specific genes, thereby affecting the production of certain proteins.

What is the TRiMTM platform?

The TRiMTM platform is Arrowhead's targeted RNAi molecule technology that uses ligand-mediated delivery for tissue-specific targeting, designed to simplify manufacturing and improve therapeutic precision.

Which diseases does Arrowhead Pharmaceuticals address?

Arrowhead's treatments target diseases such as Hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Where is Arrowhead Pharmaceuticals headquartered?

Arrowhead Pharmaceuticals is headquartered in Pasadena, California.

What are the latest developments at Arrowhead Pharmaceuticals?

For the latest news and developments, visit Arrowhead Pharmaceuticals' official website or check recent press releases and updates.

How does Arrowhead's technology benefit patients?

Arrowhead's RNAi-based therapies aim to reduce the production of proteins that cause diseases, offering potential life-changing treatments for patients.

What are some advantages of the TRiMTM platform?

The TRiMTM platform's advantages include simplified manufacturing processes and enhanced tissue-specific targeting.

Is Arrowhead publicly traded?

Yes, Arrowhead Pharmaceuticals is publicly traded on the NASDAQ under the ticker symbol ARWR.

How can I invest in Arrowhead Pharmaceuticals?

You can invest in Arrowhead Pharmaceuticals by purchasing shares through a stockbroker or an online trading platform. The company's ticker symbol is ARWR.

Arrowhead Research Corporation

Nasdaq:ARWR

ARWR Rankings

ARWR Stock Data

2.46B
118.89M
4.47%
79.71%
7.6%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PASADENA